Table 3 SUCRA results in primary and secondary outcomes for the treatment of HCAP
Treatment | Mortality | Clinical success | Microbiological success | Adverse events | ||||
|---|---|---|---|---|---|---|---|---|
SUCRA | Rank | SUCRA | Rank | SUCRA | Rank | SUCRA | Rank | |
Ceftolozane/Tazobactam | 55.2 | 4 | 43.6 | 9 | 89.6 | 1 | 61.5 | 6 |
Ceftazidime/Avibactam | 33.1 | 12 | 51.5 | 7 | 35.9 | 10 | 71.2 | 2 |
Cefiderocol | 48.6 | 5 | 32.6 | 11 | 59.2 | 5 | 66 | 3 |
Cefepime | 36 | 11 | 52.6 | 6 | 69.1 | 3 | 17.1 | 11 |
Ceftazidime | 47.5 | 6 | 4 | 13 | 9.9 | 12 | 64.2 | 5 |
Piperacillin/Tazobactam | 38.8 | 10 | 58.6 | 5 | 19.3 | 11 | 35.9 | 10 |
Doripenem | 41.9 | 9 | 64 | 4 | 37.7 | 9 | 53.4 | 7 |
Imipenem/Cilastatin | 72.2 | 2 | 66 | 3 | 44.8 | 8 | 41 | 9 |
Imipenem/Cilastatin/Relebactam | 68.9 | 3 | 80.7 | 2 | 45.8 | 6 | 45.1 | 8 |
Meropenem | 46.9 | 7 | 38.7 | 10 | 66.7 | 4 | 74.5 | 1 |
Meropenem + Colistin (AS) | 92 | 1 | 86.5 | 1 | NA | NA | NA | NA |
Colistin (IV) | 45 | 8 | 26.9 | 12 | 76.7 | 2 | 65.2 | 4 |
Ciprofloxacin | 24 | 13 | 44 | 8 | 45.3 | 7 | 4.8 | 12 |